Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.22.2.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Revenue $ 278 $ 141 $ 483 $ 292
Operating expenses:        
Cost of revenue - sales 83 65 166 135
Cost of revenue - impairment of inventory 186 159 186
Research and development 1,573 1,187 4,261 4,040
Sales and marketing 1,349 725 3,554 2,196
General and administrative 1,978 2,315 6,167 7,104
Total costs and expenses 4,983 4,478 14,307 13,661
Operating loss (4,705) (4,337) (13,824) (13,369)
Gain (loss) on change in estimated fair value of contingent royalty obligation 34 (35) (29) (152)
Loss on extinguishment of debt (237) (237)
Finance expense, net (310) (216) (1,001) (450)
Other income 5 5
Foreign currency gain (loss) 17 (4) (61) (12)
Net loss (4,964) (4,824) (14,915) (14,215)
Deemed dividends from warrant issuance (6,145)
Net loss attributable to common shareholders $ (4,964) $ (4,824) $ (14,915) $ (20,360)
Basic and diluted loss per common share:        
Net loss attributable to common shareholders $ (1.69) $ (2.00) $ (5.40) $ (8.77)
Weighted average number of common shares outstanding, basic and diluted 2,937,530 2,412,059 2,763,164 2,320,982